As the Iran war disrupts supplies, will it affect access to medicines?

397 medicines are currently listed as in shortage and more than 90% of medicines used in Australia are imported. Since July 2023 PBS rules require manufacturers to hold 4–6 months' supply onshore and the TGA can deploy measures (Section 19A imports, special dispensing permissions) to mitigate gaps. The system handles short-to-medium disruptions, but sustained global instability (>=6 months), reliance on India/China for APIs and just-in-time logistics raise material risk of broader shortages—especially for non-PBS, single-supplier, or newer medicines. Monitor evolving shortage list and geopolitical/logistics disruptions; near-term access is likely stable but vulnerabilities remain.

Analysis

Australia’s mandated on‑shore buffer creates an episodic capital reallocation: wholesalers and large distributors will absorb inventory carrying costs while smaller generic manufacturers and niche importers face margin squeeze and liquidity stress. Practically, a 4–6 month stock rule on fast‑turn SKUs is equivalent to a one‑time ~€X–€Y working capital increase (roughly 2–6 weeks of sales × 4–6 months coverage), advantaging firms with investment grade balance sheets and access to short‑term credit — a clear setup for M&A and market share consolidation among distributors within 6–18 months.

Time horizons matter. In the next 0–3 months, shocks are dominated by logistics (air/sea chokepoints) and substitution actions; 3–9 months is the stress window where mandated buffers are drawn down and shortages propagate to non‑PBS/product niches; 12–36 months is the policy/structural response phase where capital markets, subsidies or domestic capacity builds change the equilibrium. Regulatory mitigants (expedited import approvals) are an immediate dampener on price spikes, while any multi‑month blockade of major shipping corridors is the primary tail risk that would force wider rationing and reprice beneficiaries.

Second‑order plays are underappreciated: demand for pharma‑grade warehousing, cold chain and integrated distribution will rise, pushing rents and capex for specialized logistics up and creating enduring returns for industrial landlords with compliant assets. Conversely, increased inventories raise the political salience of PBS pricing and could trigger reimbursement changes or temporary subsidies that compress producer margins — a policy binary that will create episodic volatility and create windows for tactical trades around TGA decision points.

Key Decisions for Investors

• Long EBOS.AX (2% portfolio) — horizon 6–12 months. Rationale: largest ANZ distributor likely to capture increased volumes and pricing power as on‑shore buffers are implemented. Target upside 25–35% if TGA expands PBS list and distributor earnings surprise; stop‑loss 12–15% for downside if shortages normalize or policy curbs margins.
• Long Goodman Group (GMG.AX) (1.5% portfolio) — horizon 12–24 months. Rationale: specialized pharma warehousing and logistics real estate should see higher occupancy and rental reversion as on‑shore stocking rises. Expected total return 15–30% via rent growth and cap rate compression; downside 10–12% if construction oversupply or macro tightening pressures REIT multiples.
• Long Catalent (CTLT) or Lonza (LZAGY) via 12–36 month call spreads (1.5% portfolio net premium) — capped upside trade to play outsourced manufacturing demand. Structure: buy near‑ATM calls and sell higher strike to fund premium; target asymmetric payoff ~2:1 reward:risk if pharma firms accelerate on‑shoring; principal risk = demand reverts if shipping normalizes.
• Short‑term long in FDX (0.75% portfolio) — horizon 0–6 months. Rationale: acute phase increases demand for premium air shipments of APIs and finished therapies; expect near‑term yield improvement. Target 10–15% upside on 3–6 month stress window; cut losses quickly (5–8%) if air freight volumes decline as sea lanes reopen or fuel spikes materially increase operating costs.